Trevi Therapeutics Stock Price, News & Analysis (NASDAQ:TRVI)

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Trevi Therapeutics Inc (NASDAQ:TRVI) released its earnings results on Monday, August, 12th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.22. View Trevi Therapeutics' Earnings History.

Trevi Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Trevi Therapeutics.

5 analysts have issued 1-year target prices for Trevi Therapeutics' shares. Their forecasts range from $14.00 to $20.00. On average, they anticipate Trevi Therapeutics' share price to reach $16.75 in the next year. This suggests a possible upside of 347.3% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.

Press coverage about TRVI stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trevi Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Trevi Therapeutics.

Trevi Therapeutics saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 19,300 shares, a drop of 8.5% from the August 30th total of 21,100 shares. Based on an average trading volume of 13,500 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.7% of the company's stock are sold short. View Trevi Therapeutics' Current Options Chain.

Some companies that are related to Trevi Therapeutics include Rigel Pharmaceuticals (RIGL), BIOFRONTERA AG/ADR (BFRA), ProQR Therapeutics (PRQR), Puma Biotechnology (PBYI), Forty Seven (FTSV), resTORbio (TORC), Seres Therapeutics (MCRB), Xeris Pharmaceuticals (XERS), MannKind (MNKD), Provention Bio (PRVB), Evofem Biosciences (EVFM), Osmotica Pharmaceuticals (OSMT), Xenon Pharmaceuticals (XENE), Aeglea Bio Therapeutics (AGLE) and Albireo Pharma (ALBO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Canopy Growth (CGC), TransEnterix (TRXC), Bicycle Therapeutics (BCYC), Cara Therapeutics (CARA), Restoration Robotics (HAIR), Kalvista Pharmaceuticals (KALV), AbbVie (ABBV), CannTrust (CTST), Olin (OLN) and Alerian MLP ETF (AMLP).

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Trevi Therapeutics' lock-up period expires on Monday, November 4th. Trevi Therapeutics had issued 5,500,000 shares in its IPO on May 7th. The total size of the offering was $55,000,000 based on an initial share price of $10.00. After the end of Trevi Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Trevi Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (24.91%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Institutional Ownership Trends for Trevi Therapeutics.

TRVI stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC. Company insiders that have bought Trevi Therapeutics stock in the last two years include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Insider Buying and Selling for Trevi Therapeutics.

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TRVI stock can currently be purchased for approximately $3.75.

Trevi Therapeutics has a market capitalization of $66.77 million. Trevi Therapeutics employs 15 workers across the globe.View Additional Information About Trevi Therapeutics.

The official website for Trevi Therapeutics is http://www.trevitherapeutics.com/.

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]